LBH589

Vladimir Beljanski

doi:10.1016/B978-008055232-3.64517-9

LBH589

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Since the discovery that epigenetic modifications may play important roles in tumorigenesis, this discipline has become an attractive area for design of chemotherapeutics. Among the key chromatin modifying enzymes that influence gene expression are histone acetyltransferases (HATs) and histone deacetylases (HDACs). Increased expression of HDACs and disrupted activities of HATs are characteristics of several tumor types. Therefore, inhibition of HDAC represents an attractive target for development of anticancer therapies. Several deacetylase inhibitors have undergone rapid clinical development in recent years. Among these, the deacetylase inhibitor LBH589 (panobinostat) is one of the most widely studied. It has demonstrated favorable .... . © 2010

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-4
Number of pages	4
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.64517-9
State	Published - 2010
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.64517-9

Cite this

@inbook{0a58af7b2ca44e379eb1776b938a7662,

title = "LBH589",

abstract = "Since the discovery that epigenetic modifications may play important roles in tumorigenesis, this discipline has become an attractive area for design of chemotherapeutics. Among the key chromatin modifying enzymes that influence gene expression are histone acetyltransferases (HATs) and histone deacetylases (HDACs). Increased expression of HDACs and disrupted activities of HATs are characteristics of several tumor types. Therefore, inhibition of HDAC represents an attractive target for development of anticancer therapies. Several deacetylase inhibitors have undergone rapid clinical development in recent years. Among these, the deacetylase inhibitor LBH589 (panobinostat) is one of the most widely studied. It has demonstrated favorable .... . {\textcopyright} 2010",

author = "Vladimir Beljanski",

year = "2010",

doi = "10.1016/B978-008055232-3.64517-9",

language = "English",

isbn = "9780080552323",

pages = "1--4",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - LBH589

AU - Beljanski, Vladimir

PY - 2010

Y1 - 2010

N2 - Since the discovery that epigenetic modifications may play important roles in tumorigenesis, this discipline has become an attractive area for design of chemotherapeutics. Among the key chromatin modifying enzymes that influence gene expression are histone acetyltransferases (HATs) and histone deacetylases (HDACs). Increased expression of HDACs and disrupted activities of HATs are characteristics of several tumor types. Therefore, inhibition of HDAC represents an attractive target for development of anticancer therapies. Several deacetylase inhibitors have undergone rapid clinical development in recent years. Among these, the deacetylase inhibitor LBH589 (panobinostat) is one of the most widely studied. It has demonstrated favorable .... . © 2010

AB - Since the discovery that epigenetic modifications may play important roles in tumorigenesis, this discipline has become an attractive area for design of chemotherapeutics. Among the key chromatin modifying enzymes that influence gene expression are histone acetyltransferases (HATs) and histone deacetylases (HDACs). Increased expression of HDACs and disrupted activities of HATs are characteristics of several tumor types. Therefore, inhibition of HDAC represents an attractive target for development of anticancer therapies. Several deacetylase inhibitors have undergone rapid clinical development in recent years. Among these, the deacetylase inhibitor LBH589 (panobinostat) is one of the most widely studied. It has demonstrated favorable .... . © 2010

UR - https://www.scopus.com/pages/publications/84884069044

UR - https://www.scopus.com/pages/publications/84884069044#tab=citedBy

U2 - 10.1016/B978-008055232-3.64517-9

DO - 10.1016/B978-008055232-3.64517-9

M3 - Chapter

AN - SCOPUS:84884069044

SN - 9780080552323

SP - 1

EP - 4

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

LBH589

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

AMG 655

Bendamustine

Cediranib

Cite this